All go for Progen

JUNE 2010

EMBATTLED drug developer Progen Pharmaceuticals (PGL) has been granted a European patent for the preparation and use of its cancer therapeutic Muparfostat (PI-88).

Progen CEO Sue MacLeman says the patent grant will give the company greater coverage in a major pharmaceutical market.

Progen has also announced it plans to sublicence the technology to Taiwanese company Medigen Biotech Corp.

Amid board restructures and uncertainty for the biotech’s future, PGL shares have fallen by around 40 per cent in the last 12 months.

Get our daily business news

Sign up to our free email news updates.

Please tick to verify that you are not a robot

 
The MBA that helped Epic Environmental’s startup employee become GM and partner
Partner Content
Environmental engineer Romin Nejad began his career at Epic Environmental at a challeng...
Queensland University of Technology
Advertisement

Related Stories

RACQ Insurance fined $10m for failing customers on discount promises

RACQ Insurance fined $10m for failing customers on discount promises

The insurance arm of the member-owned Royal Automobile Club of...

Lovers, not fighters: Mr Yum and me&u consummate hospitality merger

Lovers, not fighters: Mr Yum and me&u consummate hospitality merger

Two leading Australian companies that have upended the status quo i...

Sunshine Coast icon Beefy's Pies acquired by RFG for $10 million

Sunshine Coast icon Beefy's Pies acquired by RFG for $10 million

The owners of award-winning Sunshine Coast family pie shop chain Be...

New research shows how Indigenous-owned businesses are creating better outcomes for their employees

New research shows how Indigenous-owned businesses are creating better outcomes for their employees

We are seeing more Indigenous businesses in Australia. This is impo...